Because this process modifies the key protein involved in tauopathies, and because OGA is located on chromosome 10q24.1 (a locus associated with late-onset AD [4, 5]), interest has grown in O-GlcNAcylation as a therapeutic target. The gene discussed is OGA; the disease is tauopathy.